Revvity (NYSE:RVTY) Shares Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Revvity, Inc. NYSE: RVTY. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on April 8th.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.

Revvity Stock Performance

NYSE:RVTY traded down $1.74 during mid-day trading on Tuesday, hitting $96.77. The company's stock had a trading volume of 148,513 shares, compared to its average volume of 1,113,533. The stock has a market cap of $11.41 billion, a price-to-earnings ratio of 43.79, a PEG ratio of 3.82 and a beta of 1.02. The business's fifty day moving average is $100.57 and its two-hundred day moving average is $110.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. Revvity, Inc. has a 1 year low of $88.53 and a 1 year high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.05. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The business's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.98 EPS. Analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, July 18th. Revvity's payout ratio is 11.91%.

Institutional Investors Weigh In On Revvity

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Assetmark Inc. raised its holdings in shares of Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after acquiring an additional 259 shares during the period. Optiver Holding B.V. purchased a new stake in Revvity in the fourth quarter valued at $33,000. Quarry LP grew its holdings in shares of Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after purchasing an additional 95 shares during the period. Millstone Evans Group LLC acquired a new stake in shares of Revvity during the 4th quarter worth about $38,000. Finally, Vermillion Wealth Management Inc. acquired a new stake in shares of Revvity during the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 86.65% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on RVTY shares. Raymond James reiterated an "outperform" rating and set a $120.00 price target (down previously from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. Robert W. Baird decreased their target price on Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 29th. Barclays reduced their price objective on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. KeyCorp lifted their target price on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, UBS Group raised shares of Revvity from a "neutral" rating to a "buy" rating and cut their target price for the stock from $145.00 to $115.00 in a research note on Thursday, May 1st. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $125.64.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.